Suchergebnisse - "Ixazomib"

PubPharm (512)

1

Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma

enthalten in: Zhongguo shi yan xue ye xue za zhi | 2024

von Chen, R. | Xue, L. | Zhou, H. | +7

2

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma : A pooled analysis from the INSURE study

enthalten in: European journal of haematology | 2024

von Lee, H. | Ramasamy, K. | Macro, M. | +10

3

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies : the DACIPHOR regimen

enthalten in: Blood advances | 2024

von Karmali, R. | Galvez, C. | Hamadani, M. | +14

4

INSURE : a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

enthalten in: Future oncology (London, England) | 2024

von Leleu, X. | Lee, H. | Zonder, J. | +10

5

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts

enthalten in: Experimental hematology | 2024

von Randall, J. | Evans, K. | Watts, B. | +10

6

Proteasome inhibitor-associated histiocytoid Sweet's syndrome : Clinical and histological similarities to Nakajo-Nishimura syndrome suggest a potential mechanism

enthalten in: The Journal of dermatology | 2024

von Cho, R. | Nakajima, S. | Kaku, Y. | +4

7

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

8

Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma

enthalten in: Leukemia & lymphoma | 2024

von Hill, B. | Chen, Y. | Jagadeesh, D. | +7

9

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma : A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

enthalten in: Cancers | 2024

von Partanen, A. | Waage, A. | Peceliunas, V. | +26

10

The EASEMENT study : A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies

enthalten in: European journal of haematology | 2024

von Ayto, R. | Annibali, O. | Biedermann, P. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[52]